Text Size

Side Effects of Pulmonary Hypertension Medications

This study is currently recruiting participants.
Verified April 2012 by Stanford University
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01571713
First received: April 3, 2012
Last updated: NA
Last verified: April 2012
History: No changes posted
  Purpose

The study seeks to analyze the patient reported effects of pulmonary hypertension medications and compare these with the side effects described on the package inserts. Side effects for these PH medications have been described in the adult population, but have never been described in the pediatric population. This information can better improve patient care and be used to characterize the side effects resultant from these medications.


Condition
Pulmonary Hypertension

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Patient Reported Side Effects of Pulmonary Hypertension (PH) Medications

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Stanford University:

Estimated Enrollment: 45
Study Start Date: August 2011
Groups/Cohorts
Study
Pediatric patients with pulmonary hypertension

Detailed Description:

As part of standard of care, patients are routinely asked about any symptoms they might be experiencing. This study seeks to quantify these symptoms for research purposes. Participants will be identified through those who attend the pediatric pulmonary hypertension clinic at LPCH. Only children who are currently on one of seven PH medications (Bosentan, Epoprostenol, Letairis, Sildenafil, Tadalafil, Treprostinil, Ventaris) will be approached. Patients who consent to be in the study will answer a brief series of questions pertaining to the presence and duration of their symptoms. These will be correlated to a list of side effects taken from Lexicomp (a medication database).

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Pediatric patients with pulmonary hypertension seen in the pulmonary hypertension clinic at Stanford Lucile Packard Children's Hospital

Criteria

Inclusion Criteria:

  • pulmonary hypertension
  • currently taking at least one of the following PH medications (Bosentan, Epoprostenol, Letairis, Sildenafil, Tadalafil, Treprostinil, Ventaris)

Exclusion Criteria:

  • >18 years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01571713

Contacts
Contact: Jeffrey Feinstein, MD, MPH 650 723 7913 jeff.feinstein@stanford.edu

Locations
United States, California
Lucile Packard Children's Hospital at Stanford Recruiting
Stanford, California, United States, 94305
Contact: Jeffrey Feinstein, MD, MPH     650-723-7913     jeff.feinstein@stanford.edu    
Principal Investigator: Jeffrey Feinstein, MD, MPH            
Sponsors and Collaborators
Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01571713     History of Changes
Other Study ID Numbers: PHSE22242
Study First Received: April 3, 2012
Last Updated: April 3, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
 Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 21, 2013